A phase 1b randomized clinical trial of CT1812 to measure Aβ oligomer displacement in Alzheimer’s disease using an indwelling CSF catheter

• Kelsie M. LaBarbera,
• Yvette I. Sheline,
• Nicholas J. Izzo,
• Carla M. Yuede,
• Lora Waybright,
• Raymond Yurko,
• Hannah M. Edwards,
• Woodrow D. Gardiner,
• Kaj Blennow,
• Henrik Zetterberg,
• Anne Börjesson-Hanson,
• Roger Morgan,
• Charles S. Davis,
• Robert J. Guttendorf,
• Lon S. Schneider,
• Steven DeKosky,
• Harry LeVine,
• Michael Grundman,
• Anthony O. Caggiano,
• John R. Cirrito,
• Susan M. Catalano,
• Mary E. Hamby

Affiliations

Kelsie M. LaBarbera

Cognition Therapeutics Inc.

Yvette I. Sheline

University of Pennsylvania

Nicholas J. Izzo

Cognition Therapeutics Inc.

Carla M. Yuede

Washington University

Lora Waybright

Cognition Therapeutics Inc.

Raymond Yurko

Cognition Therapeutics Inc.

Hannah M. Edwards

Washington University

Woodrow D. Gardiner

Washington University

Kaj Blennow

University of Gothenburg

Henrik Zetterberg

University of Gothenburg

Anne Börjesson-Hanson

Karolinska University Hospital

Roger Morgan

MedSurgPI, LLC

Charles S. Davis

CSD Biostatistics, Inc.

Robert J. Guttendorf

Aclairo Pharmaceutical Development Group, Inc

Lon S. Schneider

Keck School of Medicine of USC

Steven DeKosky

McKnight Brain Institute, University of Florida

Harry LeVine

Sanders-Brown Center on Aging, University of Kentucky

Michael Grundman

Global R&D Partners, LLC

Anthony O. Caggiano

Cognition Therapeutics Inc.

John R. Cirrito

Washington University

Susan M. Catalano

Cognition Therapeutics Inc.

Mary E. Hamby

Cognition Therapeutics Inc.